<>
According to research published by the team, the new approach creates a scalable supply of off-the-shelf immune cells that can be mass-produced, frozen, and deployed across multiple patients.
Bypassing Patient-Specific Bottlenecks
Traditional chimeric antigen receptor (CAR) T-cell therapies require extracting a patient’s own immune cells, modifying them in a laboratory, and reinfusing them. This custom process often takes several weeks and costs hundreds of thousands of dollars. By utilizing umbilical cord blood—known as a rich source of programmable, pluripotent stem cells—researchers aim to bypass individual manufacturing bottlenecks. Co-senior author Charlie Li stated that the team can generate trillions of therapeutic cells from a small quantity of cord blood stem cells in roughly six weeks, yielding thousands of potential treatment doses.
Targeting NY-ESO-1 and Mutation Risks
The technology falls under the T-cell receptor (TCR) therapy class. Researchers introduce a gene into the stem cells that programs them to produce receptors capable of recognizing NY-ESO-1, a protein expressed across several types of cancer. As these stem cells divide and mature into functional T cells, nearly all daughter cells inherit the exact same receptor target. However, cancer cells frequently mutate, hide, or stop expressing targeted proteins, allowing surviving malignant cells to evade standard single-target treatments.
Engineering the Dual-Recognition System
To address tumor evasion, the UCLA team engineered what they term AlloESO-T cells with a dual-recognition system. The first system utilizes the engineered TCR to detect NY-ESO-1, while the second system incorporates natural killer (NK) cell receptors designed to identify stress signals commonly displayed by cancer cells. According to study authors, if a tumor loses or conceals the NY-ESO-1 antigen, the engineered T cells retain a secondary pathway to detect and destroy the malignant tissue.
Preclinical Success in Ovarian Cancer Models
In preclinical testing involving ovarian cancer mouse models, a single injection of AlloESO-T cells produced prolonged tumor suppression and extended survival rates. Researchers observed that the infused cells multiplied approximately 100-fold inside the subjects, migrating directly to tumors and remaining active for weeks while largely avoiding healthy organ accumulation.
Safety Evaluations and Future Trials
Despite the positive preclinical outcomes, the technology remains in the early research phase. Investigators must complete comprehensive safety evaluations to determine whether these allogeneic cells can be effectively controlled within complex human biological environments without triggering adverse immune reactions. Clinical trials will be required before the therapy can be considered for human patients.
>
Related reading